Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 2016

View Archived Issues

Tesaro initiates phase I study of TSR-022 for advanced solid tumors

New phase I trial explores use of lentivirus alpha-gal A transduced CD34+ cells in Fabry disease

NIAID-sponsored phase I trial of yellow fever vaccine begins

GSK reflects on milestones of second quarter 2016

Methanobactin reverses mitochondrial impairment and acute liver failure in model of Wilson disease

Ono seeks Japanese approval for Opdivo for head and neck cancer

SAMD9 mutations cause new form of syndromic adrenal hypoplasia

International partnership to tackle the threat posed by antimicrobial resistance

European orphan drug designation awarded to volanesorsen for familial partial lipodystrophy

FIOCRUZ patents antituberculosis agents

University of Illinois discloses antifungal compounds

Auspex Pharmaceuticals describes modulators of melatonin receptors

Hitgen reports HDAC6 inhibitors

FDA grants breakthrough therapy designation to AVXS-101 for spinal muscular atrophy

Phase I results for Abeta oligomer receptor antagonist CT-1812

First-in-human results on LY-3002813

FDA grants fast track designation for CLBS-03 for the treatment of recent onset type 1 diabetes

Pfenex grants Jazz Pharmaceuticals rights to early-stage hematology product candidates

Omeros receives scientific advice from EMA on phase III program for OMS-721

ProterixBio earns grant from MJFF

Pfizer reports promising topline results from OCTAVE Sustain trial of Xeljanz

Editas Medicine and Fondazione Telethon and Ospedale San Raffaele form collaboration

Western Oncolytics and Pfizer enter immuno-oncology research collaboration

New company Nodthera Limited to focus on inhibitors of NLRP3

Adaptimmune Therapeutics gains access to EMA's PRIME initiative for T-cell therapy

Janssen files for approval of darunavir/cobicistat combination tablets in Japan

Supplemental application filed for Somatuline in Japan for neuroendocrine tumors

Protagonist Therapeutics receives grant to develop hepcidin mimetics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...